Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBIn an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
FDA Grants Fast Track Designation to NBTXR3 in Locally Advanced …
WEBFeb 11, 2020 · An FDA Fast Track Designation was granted to the first-in-class radioenhancer NBTXR3 with or without cetuximab (Erbitux) for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy, according to a press release from Nanobiotix. 1 NBTXR3 showed preliminary signals of antitumor activity in this patient population in ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
New Pharmacological Frontiers in Neuroendocrine Cancer Treatment
WEBNov 10, 2021 · However, we are now seeing a number of new approvals of targeted drug therapies for neuroendocrine cancers—most notably, radiopharmaceuticals known as peptide receptor radionuclide therapy (PRRT), a type of radiotherapy that targets peptide receptors to deliver localized treatment. 7. Initially offered only in …
A Decade of Thyroid Cancer Research Brings Precision Medicine to …
WEBFeb 26, 2021 · A Decade of Thyroid Cancer Research Brings Precision Medicine to the Forefront of Care. February 26, 2021. By Nichole Tucker. Article. The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer, has brought into question the management of disease as it is known today.
Evaluating the REFLECT Trial of Lenvatinib in Unresectable HCC
WEBJan 3, 2022 · EP: 12. Transcript: Aparna Kalyan, MD: The REFLECT trial was a phase 3 trial that looked at lenvatinib and comparing it to sorafenib in frontline patients with unresectable HCC [hepatocellular carcinoma]. And we should point out that this study was designed as a noninferiority trial, essentially not trying to beat sorafenib but just to see if ...
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
WEBJan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at …
Promising ADCs Emerge in Non-Small Cell Lung Cancer
WEBNov 18, 2023 · Antibody-drug conjugates (ADCS) have emerged as a pillar of therapy across several advanced cancer types, including non–small cell lung cancer (NSCLC). However, beyond confirmatory phase 3 trials, questions about optimal agent sequencing, novel combinations, and management of their toxicities remain. “There is a …
From Then to Now: How Genomic Testing for Cancer Has Expanded
WEBAug 26, 2022 · EGFR testing allowing for matching to EGFR-targeted therapies has led the charge for precision medicine in lung cancer as well as a shift in recommended testing for patients. In 2011, the American Society of Clinical Oncology first recommended that all patients with advanced NSCLC be tested for EGFR before deciding on first-line therapy.12 Since 2004, several generations of EGFR TKIs have been ...